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Abstract 
Background 
Congophilia indicates the presence of amyloid protein, an aggregate of misfolded proteins, 
implicated in the pathophysiology of preeclampsia. Recently urinary congophilia has been 
proposed as a test for diagnosis and prediction of preeclampsia.  
 
Objectives 
To determine whether urine congophilia is present in a cohort of women with preeclampsia and 
in pregnant and non- pregnant women with renal disease.  
 
Study design  
Using a Preeclampsia, Chronic Hypertension, renal disease and Systemic lupus 
erythematosus  cohort, urine samples were analysed from healthy pregnant controls (n=31), 
pregnant women with preeclampsia (n=23), gestational hypertension (n=10), chronic 
hypertension (n=14), chronic kidney disease; n=28), chronic kidney disease with 
superimposed preeclampsia (n=5) and those with chronic hypertension and superimposed 
preeclampsia (n=12). Samples from non-pregnant controls (n=10) and non-pregnant women 
with either systemic lupus erythematosus with (n=25) and without lupus nephritis (n=14) were 
analysed. 
 
For each sample, protein concentration was standardised before mixing with Congo Red, 
spotting to nitrocellulose membrane and rinsing with methanol. The optical density of the 
residual Congo Red stain was determined, Congo red retention calculated and groups 
compared with Mann-Whitney test or Kruskal-Wallis Analysis of Variance test as appropriate. 
 
Results  
Congophilia was increased in urine from women with preeclampsia (median Congo red 
retention 47% [interquartile range 22-68]) compared to healthy pregnant controls (Congo red 
retention 16% [13-21]; p=0.002), women with gestational hypertension (Congo red retention 
20% [13-27]; p=0.008) or to women with chronic hypertension (Congo red retention 17% [12-
28]; p=0.01). There were no differences in Congo red retention between pregnant women with 
chronic hypertension and normal pregnant controls (Congo red retention 17% [12-28] vs. 16 
[13-21] respectively; p=0.72). Congophilia was present in pregnant women with chronic kidney 
disease (Congo red retention 32% [14-57]), being similar to values found in women with 
preeclampsia (p=0.22) and for women with chronic kidney disease and superimposed 
preeclampsia (Congo red retention 57% [29-71]; p=0.18).  
 
Non-pregnant women with lupus nephritis had higher congophilia compared with non-pregnant 
female controls (Congo red retention 38 [17-73] vs. 9; [7-11%]; p<0.001) and non-pregnant 
women with systemic lupus erythematosus without nephritis (CRR 38 [17-73] vs. 13 [11-17%]; 
p=0.001). A significant positive correlation was observed between congophilia and 
protein:creatinine ratio (Spearman rank correlations 0.702; 95% confidence interval: 0.618 to 
0.770; p<0.001). 
 
Conclusion 
This study confirms that women with preeclampsia and chronic kidney disease without 
preeclampsia have elevated urine congophilia compared to healthy pregnant women. Non-
pregnant women with lupus nephritis also have elevated urine congophilia compared with 
healthy controls. An elevated Congo Red retention may not be able to differentiate between 
these conditions and further research is required to explore the use of congophilia in clinical 
practice.  
 
Key words; amyloid; Congo red; chronic kidney disease; preeclampsia; renal disease; 
unfolded protein response; urine congophilia.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Preeclampsia, a disease in pregnancy characterised by the development of hypertension and 
multi-organ manifestations including proteinuria, is a leading cause of maternal mortality, 
accounting for 17-24% of all maternal deaths in low income settings.1 Current theories suggest 
that preeclampsia arises from impaired placentation (trophoblast invasion of the maternal 
uterine spiral arteries), which in turn leads to placental hypoxia and ischaemia, and stimulation 
of sustained endoplasmic reticulum and oxidative stress.2-5 It has been proposed that this 
pathophysiological cascade generates the characteristic systemic symptoms of the maternal 
disease.6 Endoplasmic reticulum stress in the placenta, as in other cell types, leads to 
upregulation of the unfolded protein response pathway. 7-9 The unfolded protein response is a 
common cellular defence mechanism that promotes removal of unfolded or 
misfolded proteins to prevent potentially toxic accumulation. Activation of placental unfolded 
protein response has been shown to occur in early onset preeclampsia but not in late onset 
preeclampsia or normotensive controls.5  
 
Congo red, initially developed as a textile dye, has been used most commonly to identify 
amyloid in tissue sections by demonstration of green birefringence under crossed polarisers,10 
including identification of amyloid beta deposits at post-mortem in brain tissue from patients 
with Alzheimer’s disease.11 As a result of these associations, the presence of Congo red 
staining itself is now thought to represent protein misfolding due to its propensity to detect 
proteins with amyloid-like characteristics.12-14     
 
Previous work demonstrated the presence of urine congophilia using the Congo red ‘dot’ test, 
and the authors proposed that it carries diagnostic and prognostic potential for preeclampsia.15 
This Congo red assay is now being investigated as an innovative mobile health solution in 
countries with limited resources, as a diagnostic and prognostic tool for preeclampsia.16   
 
The aim of this study was to determine whether urine congophilia is present in a cohort of 
women with preeclampsia and in pregnant and non-pregnant women with renal disease  
 
Materials and Methods 
We conducted a retrospective analysis of samples collected as part of a prospective study. 
Samples were obtained from participants recruited to a multicentre preeclampsia, chronic 
hypertension, renal disease and SLE cohort.17 A pragmatic approach was adopted and all 
samples available for analysis within the cohort were selected and analysed and all data 
presented. The groups examined are defined in Table 1 and consisted of healthy pregnant 
controls (n=31), pregnant women with preeclampsia (n=23), gestational hypertension (n=10), 
chronic hypertension (n=14), chronic kidney disease (CKD; n=28), CKD with superimposed 
preeclampsia (n=5) and those with chronic hypertension and superimposed preeclampsia 
(n=12). Exclusion criteria were <18 years old or >50 years old, an inability or unwillingness to 
give informed consent, known HIV, Hepatitis B or C positive or a multi-fetal pregnancy.   
 
Three additional groups of non-pregnant women were assessed for urinary congophilia, 
including healthy controls (n=10), women with systemic lupus erythematosus (SLE; n=25) and 
women with lupus nephritis (n=14). The patients were identified through the Registry of 
Connective tissue diseases (10/H0405/35) at St Thomas’ Hospital. The National Health 
Service (NHS) National Research Ethics Service approved the collection and utilization of 
samples for research purposes. SLE was defined using American College of Rheumatology 
criteria for the classification of SLE with and without kidney involvement (category III, IV and V 
according to the International Society of Nephrology/ Renal Pathology Society 
glomerulonephritis classification).18,19  
 
Midstream urine samples were collected into sterile containers, centrifuged at 1400g (10 min), 
and stored in multiple aliquots at -80°C within 3 h of collection. Total protein concentration was 
quantified using the Pierce Bicinchonic Acid (BCA) Assay Kit (Life Technologies) according to 
manufacturer’s instructions, each sample being tested in triplicate. Standards were made 
according to manufacturers’ instructions to cover a range of 20 - 2000 µg/ml and also added in 
triplicate. Protein;creatinine ratio calculations were derived from total urinary protein quantified 
using the benzethonium chloride method (Roche Diagnostics) (intra-assay precision: 1-2%, 
inter-assay precision: 0.9-1.6%) and urinary creatinine concentrations measured with the 
enzymatic creatinine method (Roche Diagnostics) (urine: intra-assay coefficient of variation 
0.8% and inter-assay coefficient of variation 2.1%; serum: intra-assay coefficient of variation 
0.9%, and inter-assay coefficient of variation 1.1%). 
 
Congo red retention (CRR) was calculated following the method described by Buhimschi et 
al.15 The total protein concentration of each sample was standardised to 6.6mg/ml total protein, 
achieved either by dilution or by concentration in a vacuum centrifuge (Concentrator Plus, 
Eppendorf, Germany). Following protein standardisation, 100µl of sample was added to 2µl of 
Congo Red dye (Sigma). Samples were incubated at room temperature (60min) and 5 µl then 
spotted in triplicate onto an unsupported nitrocellulose membrane (Nitrocellulose Membrane, 
0.2µm, Bio-Rad Laboratories). After drying in air and washing with deionised water (3 min), 
Congo red was imaged (GelLogic 2200 Pro), using white light illumination and a single 
exposure of 1 sec (114m field of view; f-stop 13.2). The membrane was then washed in 
increasing concentrations of methanol (50% methanol: 3 minutes, 70% methanol: 1 minute, 
90% methanol until the red in the blank samples disappeared completely (~10 minutes)). A 
second image was then captured. Analysis was performed with Image J software. The 
background of each image (obtained from the blank control) was subtracted and the image 
inverted on the black and white axis to measure Congo red retention (rather than clearance). A 
standard area of interest was used to obtain a value for the ‘mean grey value (GV)’, the 
measure of staining density, for each spot. CRR was calculated by dividing the Grey Value of 
the spot from the second image by the Grey Value of the same spot in the first image and 
expressed as a percentage. The CRR was calculated as an average of the triplicates. The 
CRR index was performed masked to study group. Results were independently double-read 
 
Statistical analysis was performed using GraphPad Prism (Version 6). Results are presented 
as median with interquartile ranges (non- parametric distribution). Data sets were compared 
with Mann-Whitney test, Kruskal-Wallis Analysis of Variance (ANOVA) or Chi square as 
appropriate. Correlation analysis between congophilia and protein:creatinine ratios (PCR) was 
performed using the Spearman rank correlation.  
 
Results 
Baseline characteristics and outcomes for pregnant and non-pregnant study participants are 
described in Tables 2, 3 and 4. No differences in congophilia were observed between normal 
pregnant controls and those with gestational hypertension (CRR median 16% [IQR 13-21] vs. 
20% [13-27]; p=0.48) or pregnant women with chronic hypertension (CRR 17% [12-28] vs. 16 
[13-21]; p=0.72; Figure 1). Congophilia was increased in urine from women with preeclampsia 
(CRR 47% [22-68]) compared to healthy pregnant controls (CRR 16% [13-21]; p=0.002), 
women with gestational hypertension (CRR 20% [13-27]; p=0.008) or to women with chronic 
hypertension without superimposed preeclampsia (CRR 17% [12-28]; p=0.01).  
 
Congophilia also was present in pregnant women with CKD without superimposed 
preeclampsia (CRR 32% [14-57]), at comparable CRR values to women with preeclampsia 
(p=0.22) and was not significantly higher in women with CKD with superimposed preeclampsia 
(CRR 57% [29-71]; p=0.18).  
 
Non-pregnant women with lupus nephritis had significantly higher CRR values compared with 
healthy non-pregnant controls (CRR 38% [17-73] vs. 9%; [7-11]; p<0.001) and women with 
SLE without nephritis (13 [11-17]; p=0.001; Figure 2) 
 
Protein:creatinine ratios were also assessed in 174 women (excluding healthy controls). A 
significant positive correlation was observed between congophilia and protein:creatinine ratios 
(Spearman rank correlations 0.702; 95% confidence interval: 0.618 to 0.770; p<0.001: Figure 
3). 
 
Discussion 
This study has confirmed the previously reported presence of urinary congophilia, assessed by 
CRR, in women with preeclampsia but demonstrates that it is also evident in pregnant and 
non-pregnant women with other conditions associated with renal impairment. We have also 
reported a strong correlation between the magnitude of congophilia and protein:creatinine 
ratios. 
 
Strengths of this study include accurate phenotyping of participants with urine samples 
collected under standardised conditions and processed consistently to determine CRR. Post-
hoc power calculations, demonstrated that this study had sufficient power to detect a mean 
difference of 20% Congo red retention between normal pregnant women and women with 
preeclampsia (90% power) or CKD (94% power), preeclamptic women and women with 
chronic kidney disease (79% power) and between non pregnant lupus nephritis cases and 
non-pregnant controls (89% power). There was inadequate power to detect differences in 
other subgroups. In our study the group examining women with preeclampsia included those 
with term and pre-term preeclampsia. Therefore, these results may not be generalizable to 
women with preterm preeclampsia (<34 weeks gestation). Additional studies on larger cohorts 
would allow examination of differences between sub groups.   
 
Buhimschi et al reported elevated congophilia in women with superimposed preeclampsia, the 
values being similar to those observed in women with severe preeclampsia. Congophilia was 
observed in our study in women with CKD with and without superimposed preeclampsia. It is 
possible that congophilia identified in women with superimposed preeclampsia by Buhimschi 
included those with undiagnosed chronic kidney disease. Buhimschi et al also included women 
with pre-existing nephropathy (n=9) in their study, but this group was amalgamated with cases 
presenting with intrauterine growth restriction (n=20), liver and/or kidney failure of unknown 
aetiology (n=4) and anti-phospholipid syndrome (n=4). In this heterogeneous group 22% (8/37) 
had CRR levels above the 15% threshold used to define a “non–reassuring” value. The 
inclusion of a large number of normotensive participants with low proteinuria may have 
resulted in an underestimation of congophilia in women with renal disease, when merged 
within the heterogeneous group. Other limitations of our study include differences in baseline 
characteristics across groups including BMI, age, ethnicity and parity which may influence 
congophilia. 
In keeping with our findings of a significant correlation between urinary congophilia and 
protein:creatinine ratio, Buhimschi et al demonstrated a significant correlation between 24 h 
urine collection and urinary congophilia. In our study, the association was examined across all 
study groups. Due to limited numbers, the relationship was not addressed between CRR and 
protein:creatinine ratios in individual study groups. 
   
Placental endoplasmic reticulum stress is considered central to the pathophysiology of 
preeclampsia. Further research is required to determine the source of these misfolded proteins 
and to examine whether they are associated with ER stress as has been demonstrated in 
other pathology 7-9 The median gestational age at delivery was 38 weeks, indicating that the 
majority fell into the late-onset sub-type of the syndrome. Activation of unfolded protein 
response pathways is no different in placentas from such patients compared to normotensive 
age-matched controls, and the normal ultrastructural appearance of the endoplasmic reticulum 
indicates no accumulation of misfolded proteins in the syncytiotrophoblast.5    
 
In clinical practice particularly in low to middle income countries, chronic kidney disease is 
prevalent and is estimated to affect up to one in ten women of reproductive age, making 
confirmation of superimposed preeclampsia challenging.20-24 These figures are likely to 
increase in parallel with the increasing prevalence of hypertensive disease and diabetes in 
these countries. Endoplasmic reticulum stress and the unfolded protein response can be 
activated by many processes, all of which have been implicated in the pathogenesis of 
preeclampsia.25-27 In addition, preeclampsia shares many common aetiological and 
pathological features with other diseases in which the unfolded protein response pathway has 
been implicated via endoplasmic reticulum stress, including cardiovascular disease,28-30 renal 
disease,31,32 cerebrovascular disease,33-37 stroke, metabolic disorders, cancer, 
inflammatory disease, diabetes mellitus and neurodegenerative disease.38  
 
This study confirms that women with preeclampsia and chronic kidney disease without 
preeclampsia have elevated urine congophilia compared to healthy pregnant women. Non-
pregnant women with lupus nephritis also have elevated urine congophilia compared with 
healthy controls. An elevated Congo Red retention may not be able to differentiate between 
these conditions and further research is required to explore the use of congophilia in clinical 
practice.
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TABLE 1: DEFINITIONS USED FOR CLASSIFICATION OF WOMEN  
Definition Criteria 
Healthy control 
women 
 No risk factors for preeclampsia 
 No history of preeclampsia, hypertension, diabetes, renal disease, 
connective tissue disease or anti-phospholipid antibody syndrome  
 Systolic blood pressure <140mmHg  
 Diastolic blood pressure <90mmHg  
 No protein on dipstick analysis of midstream urine 
 Not in labour 
Gestational 
Hypertension 
 Previously normotensive 
 Two recordings of systolic blood pressure ≥140mmHg or diastolic 
blood pressure ≥ 90mmHg greater than 4 hours apart  
 After 20 weeks’ gestation  
 Not in labour 
Preeclampsia  Gestational Hypertension 
AND 
 Proteinuria of >300mg protein over 24 hours, (or protein:creatinine 
ratio of >30mg/mmol); 
Superimposed 
preeclampsia on 
chronic 
hypertension; 
Hypertension 
  New onset of proteinuria >300mg protein over 24 hours, (or 
protein:creatinine ratio of  >30mg/mmol); 
OR 
Additional features – severe persistent right upper quadrant pain or 
epigastric pain unresponsive to mediation or alanine transaminase < 
already present 71U/l or platelet count <100,000/µl or pulmonary oedema or new onset 
cerebral or visual disturbance 
Superimposed 
preeclampsia 
Proteinuria already 
present 
 Two recordings of systolic blood pressure ≥140mmHg or diastolic 
blood pressure ≥ 90mmHg greater than 4 hours apart  
OR 
 Additional features as listed above 
Superimposed 
preeclampsia 
Hypertension and 
proteinuria already 
present 
 Development of severe hypertension (Systolic blood pressure 
≥160mmHg or diastolic blood pressure ≥110mmHg)  
AND 
 Greater than two fold increase in proteinuria above 300mg protein 
over 24 hours, (or protein:creatinine ratio of >30 mg/mmol); 
OR 
Additional features as listed above 
Chronic 
Hypertension 
 Primary or secondary causes of hypertension 
Chronic Kidney 
Disease 
 According to Kidney Disease Outcomes Quality Initiative (KDOQI) 
guidelines pre-pregnancy  
OR 
 Persistent proteinuria (>30mg/mmol (protein:creatinine ratio) before 
20 weeks’ gestation  
OR  
 Any recorded serum creatinine >70μmol before 20 weeks’ gestation 
without risk factors for acute kidney injury. 
Table 2: Participant characteristics at sampling in the pregnant groups. Values are presented as n (%) or median (interquartile ranges). 
Variable Healthy 
pregnant 
controls 
(n=31) 
Preeclampsia 
(n=23) 
Chronic 
kidney 
disease 
(CKD) 
(n=28) 
Gestational 
hypertensio
n 
(n=10) 
Chronic 
hypertension 
(n=14) 
Superimposed 
preeclampsia  
on chronic 
hypertension 
(n=12) 
Superimposed 
preeclampsia 
on CKD 
(n=5) 
 
P-Value 
Age (years)  32 (30–
35) 
29 (27-34) 34 (29-38) 30 (29-31) 32 (29-40) 37 (34-42) 24 (22-32) 0.007 
Ethnicity 
(n;%) 
White 
European 
21 (68) 6 (26) 15 (54) 5 (50) 7 (50) 3 (25) 2 (40) 0.050 
BMI (kg/m2) 24 (22-
26) 
30 (24-34) 24 (23-30) 32 (22-39) 29 (26-34) 32 (26-37) 33 (27-36) 0.002 
Nulliparous 
(n;%) 
21 (68) 15 (65) 13 (47) 7 (70) 6 (43) 4 (33) 4 (80) 0.170 
Gestational 
age at 
sampling 
34 (33-
37) 
35 (34-36) 30 (21-34) 37 (35-39) 29 (27-32) 35 (34-37) 33 (32-35) 0.018 
 
(weeks) 
Systolic 
Blood 
Pressure at 
booking 
(mmHg) 
110 (100-
119) 
118 (111-
124) 
120 (116-
126) 
 
123(116-
130) 
120 (114-
135) 
134 (129- 140) 121 (112- 131) <0.0001 
Diastolic 
Blood 
pressure at 
booking 
(mmHg) 
66 (60-
72) 
74 (69-82) 78 (70-88) 72 (63-82) 80 (70- 85) 91 (87- 99) 74 (70-87) <0.0001 
Systolic 
Blood 
Pressure at 
sampling 
(mmHg) 
123 (113-
136) 
140 (133- 
151) 
118 (114-
134) 
138 (126- 
140) 
132 (125- 
135) 
145 (141- 155) 138 (136- 156) <0.0001 
Diastolic 
Blood 
75 (67- 
89) 
87 (76- 89) 78 (70-84) 87 (76- 90) 89 (82- 92) 92 (85- 100) 86 (84- 88) <0.0001 
pressure at 
sampling 
(mmHg) 
Protein:creati
nine ratio 
(mmol/ml) 
10 (0-14) 62 (35-132) 57 (28-
112) 
14 (13-22) 11 (5-14) 27 (17-44) 76 (62 -261) <0.0001 
Congo red 
retention (%) 
16 (13- 
21) 
47 (22- 68) 32 (14- 57) 20 (13-27) 17 (12- 28) 20 (13- 49) 57 (29- 71) 0.001 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Birth outcomes in the pregnant groups. Values are presented as n (%) or median (interquartile ranges). 
Variable Healthy 
pregnant 
controls 
(n=31) 
Preeclampsia 
(n=23) 
Chronic 
kidney 
disease 
(CKD) 
(n=28) 
Gestational 
hypertension 
(n=10) 
Chronic 
hypertension 
(n=14) 
Superimposed 
preeclampsia  
on chronic 
hypertension 
(n=12) 
Superimposed 
preeclampsia 
on CKD 
(n=5) 
 
P value 
Gestational 
age at 
delivery  
40 (39-
41) 
38 (35-38) 38 (37- 
39) 
40 (38-40) 40 (39- 40) 37 (37- 37) 34 (33- 37) <0.0001 
Mode of 
delivery (% 
Caesarean 
section) 
6 (19) 14 (50) 17 (61) 4 (40) 5 (36) 9 (75) 5 (100) 0.0006 
Birthweight 3600 
(3210- 
3885) 
2400 (2100- 
2900) 
2925 
(2500- 
3200) 
3310 (2973- 
3773) 
3350 (3120- 
3960) 
2750 (2473-
3105) 
2050 (1562- 
2725) 
<0.0001 
Neonatal 
unit 
admission 
0 (0) 7 (30) 1 (4) 1 (10) 1 (7) 1 (8) 1 (20) 0.959 
  
Table 4: Participant characteristics from non-pregnant groups. 
Variable Non-pregnant 
controls 
(n=10) 
Non-pregnant SLE 
(n=14) 
Non-pregnant lupus 
nephritis (n=25) 
P Value 
Age (years; range) 34 (28- 38) 38 (35-45) 36 (30-43) 0.27 
Ethnicity (n; %)  
White European 
7 (67) 9 (64) 13 (48) 0.402 
Protein:creatinine ratio (mmol/ml) Not measured 9 (1-15) 51 (17- 123) 0.004 
Congo red retention (%) 9 (7- 11) 13 (11- 17) 38 (17- 73) <0.001 
 
 
 
 
 
 
 
 
Figure 1: Congo red retention index in pregnant participants 
 
NP normal pregnant controls; n=31; PE preeclampsia; n=23; CKD chronic kidney disease; n=28; GH Gestational hypertension; n=10; 
CHT chronic hypertension; n=14; CHT siPE chronic hypertension with superimposed preeclampsia; n=12; CKD siPE chronic kidney 
disease with superimposed preeclampsia; n=5.. Congophilia was increased in urine from women with preeclampsia (CRR 47% [22-68]) 
compared to healthy pregnant controls (CRR 16% [13-21]; p=0.002), Congophilia also was present in pregnant women with CKD 
without superimposed preeclampsia (CRR 32% [14-57]) 
 
 
Figure 2: Congo red retention index in non- pregnant women 
 
Non-pregnant controls (n=10), non-pregnant women with systemic lupus erythematosus (SLE) without lupus nephritis (n=14), non-
pregnant women with SLE with lupus nephritis (n=25). Non-pregnant women with lupus nephritis had significantly higher CRR values 
compared with healthy non-pregnant controls (CRR 38% [17-73] vs. 9%; [7-11]; p<0.001) and women with SLE without nephritis (13 
[11-17]; p=0.001) 
 
 
Figure 3: Quantitative relationship of urine congophilia with protein:creatinine ratio.  
 
A significant positive correlation was observed between congophilia and protein:creatinine ratios p<0.001). 
